retatrutide fda status 2025 Is Approved? Current (2026) Retatrutide (LY3437943) — Dosing, Side
Description
It doesnt look like a medical miracle, but in its saliva lives exendin-4, a peptide very similar to human GLP-1 but much harder for DPP-4 to destroy
Sales were modest, and by 2017 GSK decided to withdraw albiglutide from the market for commercial reasons
The prior authorization process for GLP-1s averages 2 to 6 weeks, with initial denial rates for weight loss use hitting 30% to 50%
REFERENCES 1 Wilding JPH, Batterham RL, Calanna S, et al
These medications are covered for other clinically appropriate needs
